Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BerGenBio ASA ( (BRRGF) ) just unveiled an announcement.
BerGenBio ASA has announced that it will hold an Extraordinary General Meeting virtually on 4 August 2025. The company is encouraging all shareholders to participate in the meeting by registering through their website or VPS Investor Services by 31 July 2025. This meeting is a significant opportunity for shareholders to exercise their rights and engage with the company’s strategic decisions.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA is a biotechnology company based in Norway, primarily focused on developing innovative drugs for the treatment of aggressive diseases, including cancer. The company operates within the pharmaceutical industry and aims to address significant unmet medical needs through its research and development efforts.
Average Trading Volume: 325,832
Current Market Cap: NOK54.57M
For a thorough assessment of BRRGF stock, go to TipRanks’ Stock Analysis page.